Our results indicated that PLD treatment increased protein levels of p-AKT, p-GSK-3βSer9, and Nrf2, and downregulated the phosphorylation of NF-κB p65 in rats with LPS-induced PD. The gene discussed is GPLD1; the disease is Parkinson disease.